* ProCyte Corp., of Kirkland, Wash., gained clearance to begin aclinical trial in the U.K. of the wound-healing agent, prezatide copperacetate. The study is expected to enroll 36 patients who have chronicvenous leg ulcers.

* Sparta Pharmaceuticals Inc., of Horsham, Pa., began a Phase I trialof RII retinamide, a retinoid compound, for myelodysplasticsyndromes, which are bone marrow disorders. The clinical study isthe first for Sparta, which licensed the drug candidate from theInstitute of Materia Medica in Beijing, China.

* VIMRx Pharmaceuticals Inc., of Stamford, Conn., said it isrelocating its headquarters to Wilmington, Del.

(c) 1997 American Health Consultants. All rights reserved.